Peptide education
Oxytocin
Pitocin · Synthetic oxytocin · OXT · Oxytocic hormone
Oxytocin is a nine-amino-acid hormone with two public lives. In the hospital it is an approved obstetric injection used to start or strengthen labor and to control postpartum bleeding, one of the most established peptide drugs in existence. Online it is sold as a bonding, trust, libido, and social-ease spray, a reputation built on intranasal research that turned out to be fragile. The gap between those two lives is the whole story.
The obstetric evidence is excellent and the social evidence is weak: the trust finding that launched the hype failed a large registered replication, and the big autism and schizophrenia-cognition trials came back mixed or negative. One small dementia-apathy trial is the bright spot, and it is still preliminary.
Overview
Quick answer
Pitocin-style injectable oxytocin, compounded oxytocin nasal spray, historical Syntocinon nasal products, intranasal research material, and research-use online vials put the same hormone name into very different settings. Route, dose, device, formulation, monitoring, and product controls change what can be inferred.
What is oxytocin?
An endogenous nonapeptide hormone. As a drug it is a sterile obstetric injection; as a research tool it is an intranasal spray used to probe how people process social cues, stress, and emotion.
What is it actually approved for?
U.S. labeling covers medically indicated induction or stimulation of labor, postpartum bleeding control, and certain abortion-management contexts, all by monitored injection. No U.S. approval covers autism, social anxiety, bonding, libido, trust, or any intranasal neuropsychiatric use; the old Syntocinon nasal product was for milk ejection, not the brain.
Why do people talk about nasal oxytocin?
Because a nasal spray that nudges social behavior is a compelling idea, and early studies produced real task-level effects on trust, face processing, and emotion recognition. The follow-through was rougher: the trust effect failed a large replication, and the bigger autism and schizophrenia trials did not deliver broad benefit.
What routes and amounts show up in sources?
The label runs from IV infusion starting at 1 to 2 mU/min for labor to 10 units IM after delivery. Intranasal studies used 24 to 80 IU doses: single 24 IU administrations in couples experiments, 48 IU/day for six weeks in adult autism, 24 IU twice daily for twelve weeks in schizophrenia cognition, 72 IU every third day for dementia apathy, and 80 IU twice daily for a week in an opioid-cue laboratory study.
Why is "love hormone" too simple?
Oxytocin changes how salient social cues feel, and the direction depends on the person, the context, and the task, sometimes toward trust, sometimes toward wariness. A molecule that context-dependent does not compress into a spray-bottle slogan.
Reported practice
Commonly reported protocol
Community intranasal use. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
FDA-reviewed labels support injectable oxytocin in defined obstetric settings. That is the strongest clinical footing for the compound name.
Adult and pediatric intranasal trials did not produce a clean broad social-function win, although biomarker and age-subgroup hypotheses remain research questions.
An early trust-game study helped popularize the trust claim, but a large registered replication did not reproduce the key trust effect.
A multicenter phase 2a/2b trial reported that 72 IU every third day was well tolerated and associated with a small apathy reduction. That result is preliminary and it does not turn nasal oxytocin into routine dementia care.
Meta-analyses have explored dose and symptom findings, but a randomized cognition trial using 24 IU twice daily for 12 weeks did not significantly improve cognition versus placebo.
FDA compounding materials, nasal spray CMC guidance, and an oxytocin nasal spray inspection finding show the quality stakes behind a nasal claim. One FDA inspection example involved non-pharmaceutical-grade water and non-pharmaceutical-grade oxytocin in non-sterile oxytocin nasal spray or sublingual production.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Oxytocin is FDA-approved for autism, social anxiety, bonding, libido, or trust. | No. FDA-reviewed oxytocin labels support obstetric injectable use. The neuropsychiatric and social-behavior material is investigational intranasal research or online marketing discussion. | Oxytocin signaling is relevant to social behavior and stress processing, but a pathway does not create an approved neuropsychiatric indication. | Clinic pages, forums, and peptide-market pages commonly use bonding, intimacy, social anxiety, or libido language, but those materials are not approval records or clinical results. | The approved product record is obstetric. It does not cover consumer social or neurocognitive use. |
| Oxytocin reliably increases trust or bonding. | The original trust-game study reported an acute trust effect, but a large registered replication found no effect in the main trust condition. | Oxytocin can alter social salience, face processing, amygdala activity, and fear-recognition tasks. Those effects depend on person, context, dose, timing, and task. | The "love hormone" phrase appears often in media, clinic, and online discussion. It compresses a complicated signal into a marketing hook. | Trust and bonding claims are tied to the specific lab task; they do not become a general consumer promise. |
| Intranasal oxytocin improves core autism symptoms. | The autism evidence is mixed. Adult ASD work at 48 IU/day for 6 weeks did not make a case for continuous treatment alone at that dose and duration, a large pediatric trial did not establish a broad social-function benefit, and a young-child trial found no overall benefit while raising possible subgroup questions. | Biomarker work suggests oxytocin biology may differ across autism subgroups, but that has not yet produced a stable treatment rule. | Autism-related online discussion often moves faster than the clinical trials. The key question is which trial, which population, and which endpoint are being cited. | Worth studying, but not an established autism treatment. |
| Oxytocin helps schizophrenia cognition or symptoms. | Schizophrenia meta-analyses have reported mixed or dose-sensitive signals, but the 24 IU twice-daily cognition trial over 12 weeks did not significantly improve cognition compared with placebo. | Social cognition and salience pathways make the research plausible, but plausibility has not become a reliable cognition treatment. | Nootropic-style discussion may use the cognition angle more strongly than the trial evidence supports. | Not supported as a broad cognition claim. |
| Oxytocin may help apathy in frontotemporal dementia. | The FOXY phase 2a/2b trial reported that 72 IU every third day was well tolerated and associated with a small reduction in apathy. | Frontotemporal dementia can involve social behavior and motivation changes, which makes oxytocin a plausible research probe. | The notable signal here comes from a named human trial, not from forum demand or clinic marketing. | The most notable current neuro finding, but still preliminary. |
| Oxytocin is a libido or intimacy enhancer. | Sexual and couples studies exist, including single-dose intranasal experiments, but they are small and mixed rather than treatment-grade evidence. | Oxytocin is involved in bonding, stress, and sexual physiology, which explains why the claim is popular. | Clinic and compounded-spray marketing frequently emphasizes intimacy, bonding, or relationship language. | Discussable as a source of demand and small-study interest, not as a settled libido drug. |
| What can a vendor COA tell you about an oxytocin nasal spray or vial? | This is a finished-product issue. FDA materials distinguish approved products from compounded and unapproved drugs, and nasal products require controls far beyond a peptide identity or purity screenshot. | Dose reproducibility, droplet size, device performance, sterility, endotoxin, impurities, concentration, storage, and lawful manufacturing all affect risk. | Vendor pages advertise research-use oxytocin, purity percentages, and COAs. Those claims describe the market, but they leave out nasal-device performance, sterility, endotoxin, concentration, storage, and lawful manufacturing. | A COA may be one useful document, while pharmaceutical-grade nasal oxytocin depends on finished-product controls, device performance, sterility, concentration, storage, and lawful manufacturing. |
Bottom line
Main takeaway
Oxytocin is a legitimate hospital drug for labor and postpartum bleeding, and an unproven nasal spray for nearly everything the internet loves it for.
Match each claim to its source: an FDA obstetric label, a failed trust replication, mixed autism and schizophrenia trials, one promising dementia-apathy study, and a great deal of marketing, roughly in that order of strength.
Anchor on the FDA labels for what approval covers, the Declerck registered replication for the trust story, the Yamasue, Sikich, and Guastella autism trials, the Imamoglu cognition trial, and FOXY for the apathy signal; FDA compounding and nasal-spray CMC material covers the product side.
Identity
What it is
Oxytocin is released from the posterior pituitary and acts on uterus, breast, and brain. The peripheral effects are concrete: it contracts uterine smooth muscle and ejects milk. The central effects are real but slippery, modulating how people read faces, threat, and social cues depending on dose, timing, and context.
As a medicine it is old and dependable. Synthetic oxytocin injection is FDA-approved for labor induction or stimulation and postpartum hemorrhage, backed by decades of obstetric evidence and monitoring protocols. That is the strongest human evidence attached to any peptide name on the gray market.
As a social drug, the evidence keeps slipping. The trust-game result made oxytocin famous, and a large registered replication found no trust effect. Adult and pediatric autism trials at several doses were mixed or negative. A twelve-week schizophrenia cognition trial missed its endpoint. The FOXY trial's small apathy reduction in frontotemporal dementia is the one result that still looks promising.
The market ignores the slippage. Compounded sprays and research-use vials are sold against bonding, intimacy, and social-anxiety language, with COAs that say nothing about the nasal device, delivered dose, or sterility, and nothing about whether intranasal oxytocin does anything dependable in the first place.
How people talk about it online
Clinic and compounder pages sell oxytocin spray against intimacy, bonding, libido, and social ease, usually in the 24 to 80 IU range borrowed from research protocols. That borrowing skips the part where the research itself has struggled to replicate.
Forum reports run warm and cold: some users describe noticeable social ease or mood shifts, others feel nothing at all. Product, dose, timing, and expectation are all uncontrolled, so even the detailed reports cannot say what oxytocin did.
The quality story is concrete: an FDA inspection documented non-sterile oxytocin nasal production using non-pharmaceutical-grade water and non-pharmaceutical-grade drug substance. A spray marketed on feelings still has to be manufactured like a drug.
Use context
Routes, doses, and cycle patterns
Oxytocin use patterns split sharply by setting. The approved label describes monitored obstetric injection. Human neuro studies usually use intranasal IU schedules under study conditions. Clinic, forum, and gray-market discussion centers on nasal sprays or research-use products, where dosing and product quality are much less reliable.
Human studies and product labels
Labor induction or stimulation label pattern
- Purpose
- Medically indicated initiation or stimulation of uterine contractions
- Context
- FDA obstetric label
- Route
- Intravenous infusion
- Amount
- Start no more than 1 to 2 mU/min; increase by no more than 1 to 2 mU/min
- Frequency
- Continuous infusion adjusted until a contraction pattern similar to normal labor is established
- Duration
- Obstetric monitoring period; exact duration depends on clinical course
This is a hospital obstetric infusion pattern with fetal and maternal monitoring. It is not a wellness, mood, or social-use schedule.
Postpartum label pattern
- Purpose
- Postpartum uterine bleeding or hemorrhage control
- Context
- FDA obstetric label
- Route
- Intramuscular injection
- Amount
- 10 units after delivery of the placenta
- Frequency
- Single postpartum label-described administration
- Duration
- Immediate postpartum care context
The route, timing, and indication are specific to obstetric care. The same number does not carry into nasal or consumer peptide use.
Incomplete or inevitable abortion label pattern
- Purpose
- Uterine contraction support in the label-described abortion-management context
- Context
- FDA obstetric label
- Route
- Intravenous infusion
- Amount
- 10 units added to 500 mL
- Frequency
- Infused at 20 to 40 drops per minute
- Duration
- Label-described clinical procedure context
This is supervised obstetric care and has no direct bearing on intranasal social, mental-health, or gray-market routines.
Adult autism spectrum disorder trial
- Purpose
- Social impairment and core autism symptom research
- Context
- Randomized adult ASD trial
- Route
- Intranasal
- Amount
- 48 IU/day
- Frequency
- Daily study treatment
- Duration
- 6 weeks
The authors did not recommend continuous treatment alone at this dose and duration based on the trial outcome.
Schizophrenia cognition trial
- Purpose
- Cognition in schizophrenia
- Context
- Randomized clinical trial
- Route
- Intranasal
- Amount
- 24 IU
- Frequency
- Twice daily
- Duration
- 12 weeks
This schedule did not significantly improve cognition versus placebo, which is why cognition claims need restrained wording.
Frontotemporal dementia apathy trial
- Purpose
- Apathy in frontotemporal dementia
- Context
- Multicenter phase 2a/2b trial
- Route
- Intranasal
- Amount
- 72 IU
- Frequency
- Every third day
- Duration
- Not reported in the citation record used here; the dose schedule alone does not establish a repeat-use course.
This is the most notable current neuro finding in the cited human studies: well-tolerated exposure with a small apathy reduction, still investigational.
Opioid-use cue-reactivity laboratory study
- Purpose
- Stress or cue-reactivity research in opioid-use disorder
- Context
- Human laboratory study
- Route
- Intranasal
- Amount
- 80 IU
- Frequency
- Twice daily
- Duration
- 7 days
This study supports a narrow laboratory-research context, not a general addiction-treatment claim.
Couples sexual-behavior experiment
- Purpose
- Sexual or relationship-behavior research
- Context
- Small human experiment
- Route
- Intranasal
- Amount
- 24 IU
- Frequency
- Single administration
- Duration
- Acute experimental session
This is one reason libido and intimacy claims appear online, but it is far from an established sexual-medicine indication.
Real-world discussion
Community intranasal use
- Purpose
- Social, mood, and sexual discussion
- Context
- Clinics, forums, and compounders
- Route
- Intranasal spray
- Amount
- Community and clinic descriptions commonly mirror the 24 to 80 IU per administration range used in human intranasal studies.
- Frequency
- As needed or once daily in most descriptions
- Duration
- Episodic rather than cycled in most reports
Oxytocin is a prescription hormone with real labeled uses; intranasal cognitive and social effects in studies have been inconsistent across replication attempts. Shared here as context, not instruction.
What varies
- Goal matters: labor induction, postpartum hemorrhage control, autism symptoms, cognition, apathy, libido, social anxiety, and bonding are different claims.
- Route matters: IV and IM label patterns involve monitored obstetric care; intranasal exposure raises delivery and brain-exposure questions.
- Timing matters: acute lab tasks, six-week autism treatment, 12-week schizophrenia treatment, and every-third-day apathy dosing use different exposure windows and endpoints.
- Product format matters: an approved sterile injection, a compounded nasal spray, and a research-use vial have different controls.
Human data
Human evidence
The strongest human evidence for oxytocin is obstetric: FDA-reviewed labeling, uterotonic trials, and decades of monitored use for labor and postpartum bleeding. The intranasal neurobehavioral evidence is extensive and mostly disappointing. The flagship trust finding did not survive a large registered replication, autism trials across ages were mixed or negative, and a twelve-week schizophrenia cognition trial found no benefit over placebo. The FOXY frontotemporal-dementia trial's small apathy reduction is the most encouraging current signal, and it still needs confirmation. No cited study supports consumer use for bonding, libido, social anxiety, or general cognition.
Evidence maturity
Oxytocin is an approved obstetric injection, while the intranasal social and neuropsychiatric evidence remains mixed, replication-challenged, and unapproved.
A characterized nine-amino-acid hormone with established uterine, milk-ejection, and context-dependent central signaling.
FDA-approved injectable oxytocin is used for labor induction or stimulation and postpartum bleeding under monitored hospital care.
The early trust finding failed a large registered replication, and larger autism and schizophrenia-cognition trials were mixed or negative.
A multicenter phase 2a/2b trial reported a small apathy reduction in frontotemporal dementia, the most notable current positive neuro finding.
Compounded and research-use nasal sprays market bonding and libido claims without any neuropsychiatric approval or finished-product controls.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| FDA obstetric labeling | Pregnant or postpartum patients in label-described obstetric contexts | FDA-reviewed prescribing information | Approved injectable oxytocin | Supports oxytocin injection use in medically indicated induction or stimulation of labor, postpartum bleeding or hemorrhage contexts, and certain abortion-management contexts. | Does not answer intranasal neuropsychiatric, social, libido, bonding, autism, nootropic, or gray-market product claims. | Strong |
| Postpartum hemorrhage prevention evidence | Obstetric trial populations in uterotonic evidence reviews | Systematic review and network meta-analysis | Uterotonic medicines in obstetric care | Places oxytocin in a mature uterotonic evidence context. | Obstetric comparative evidence does not create instructions for non-obstetric or consumer peptide use. | Strong |
| Trust-game research and replication | Healthy adult laboratory participants | Acute behavioral study followed by registered replication | Intranasal experimental research | Early work reported increased trust, but a larger replication did not reproduce the key effect. | Too narrow for broad trust, bonding, or relationship claims. | Weak |
| Autism spectrum disorder trials | Adults, children, adolescents, and young children with autism spectrum disorder | Randomized intranasal treatment studies and biomarker analysis | Investigational intranasal oxytocin | Larger and more recent studies were mixed or negative overall, while biomarker and subgroup questions remain open. | Too mixed and subgroup-dependent to describe oxytocin as an autism treatment. | Weak |
| Schizophrenia cognition and symptom literature | People with schizophrenia | Meta-analyses and randomized cognition trial | Adjunctive investigational intranasal oxytocin | Mixed meta-analytic findings did not translate into a significant cognition improvement in the 24 IU twice-daily 12-week trial. | Too weak for broad cognition or negative-symptom marketing claims. | Weak |
| FOXY frontotemporal dementia apathy trial | People with frontotemporal dementia and apathy | Multicenter phase 2a/2b trial | Investigational intranasal oxytocin | Reported tolerability and a small apathy reduction with 72 IU every third day. | Preliminary signal that needs confirmation before being treated as clinical practice. | Moderate |
| Sexual and relationship experiments | Couples or sexual-behavior study participants | Small acute human studies | Experimental intranasal oxytocin | Provides small-study context behind intimacy and libido interest. | Mixed and narrow, with no approved sexual-medicine product claim behind it. | Weak |
Cautions
Safety and unknowns
- Injectable oxytocin is not casual. FDA labeling includes uterine hyperstimulation, fetal compromise, uterine rupture, fetal or neonatal adverse events, cardiovascular effects, severe water intoxication, convulsions, coma, and maternal death from water intoxication.
- Oxytocin has antidiuretic and pressor properties related to its structural relationship with vasopressin, so fluid balance and cardiovascular context matter.
- Intranasal trial adverse events are usually less dramatic than obstetric overdose warnings, but long-term repeated neuropsychiatric use is still not fully defined. Autism safety reviews mention nasal discomfort, tiredness, irritability, diarrhea, skin irritation, thirst, urination changes, constipation, and a temporary gynecomastia report in one adult ASD study.
- Delivery remains uncertain. Nasal administration does not guarantee a predictable amount at relevant brain targets, and blood, saliva, or plasma oxytocin measures do not settle that question.
Product quality
A vial label is only a starting point
Approved oxytocin injection is a regulated finished drug product. Compounded nasal spray and research-use online products lack that same reviewed device, formulation, release, and monitoring context.
FDA materials state that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness, or quality before marketing.
FDA nasal spray CMC expectations include dose reproducibility, droplet size, plume geometry, device function, extractables, formulation controls, and stability. A purity claim or COA covers only a small part of that finished-product picture.
FDA inspection records documented oxytocin nasal spray quality failures involving non-pharmaceutical-grade water and non-pharmaceutical-grade oxytocin in non-sterile products.
Route and formulation
IV, IM, and nasal products have different exposure, monitoring, and device-performance questions.
Identity and concentration
A label name cannot confirm the vial or spray contains the intended peptide at the intended amount.
Sterility and endotoxin
Injectable and nasal products can carry contamination risks outside the scope of a generic purity number.
COA scope
COAs vary in method, lot matching, date, and what they actually test. They do not replace finished-drug release controls.
Marketing claims
Biology or lab studies do not automatically support disease, libido, social-anxiety, or structure-function marketing.
Mechanism
How it is proposed to work
Peripherally, oxytocin causes uterine smooth-muscle contraction through receptor-linked calcium signaling. Centrally, it appears to change how some people process social cues, threat, stress, faces, and salience, but those effects depend heavily on context and do not behave like a universal prosocial switch.
FDA labeling describes uterotonic action in myometrium and notes that receptor concentration rises markedly during pregnancy and labor.
Oxytocin and vasopressin are structurally related, which helps explain residual antidiuretic and pressor effects and why water intoxication is a serious label warning.
Intranasal studies have reported changes in amygdala reactivity, emotion recognition, face salience, and timing-dependent neural effects, but the central delivery and biomarker interpretation remain unsettled.
The most defensible brain explanation is context-sensitive social salience, not a simple bonding, trust, or libido mechanism.
Oxytocin is a nine-amino-acid hypothalamic hormone acting at OXTR receptors in uterus, breast, and brain. Peripheral effects (labor, milk ejection) are well established; the intranasal central-effects literature for social cognition has proven difficult to replicate.
FAQ
Common questions
Is oxytocin a general bonding or social-confidence peptide?
No. The strongest approved evidence is obstetric Pitocin. Neuro-social and intranasal claims need their own data; obstetric labeling does not answer them.
Why focus on obstetric medicine?
That is where the strongest regulated product evidence sits. Pitocin labeling centers on uterine contraction and obstetric use, while systematic-review evidence places oxytocin in a uterotonic postpartum-hemorrhage context.
Does Pitocin evidence apply to intranasal or wellness-clinic oxytocin?
No. Product route, formulation, sterility, labeling, supervision, and indication differ. Pitocin evidence is for the approved obstetric product, not non-approved nasal sprays or online peptide products.
Details
Technical details
Sources
References
- 1.
DailyMed. PITOCIN- oxytocin injection prescribing information 2026.
Accessed 2026-06-09.
Current structured label source for Pitocin product identity, obstetric indications, uterine-motility mechanism, water-intoxication warning context, and product-quality framing.
- 2.
FDA. Pitocin (oxytocin injection, USP) supplemental approval letter 2021.
Accessed 2026-06-09.
FDA supplemental approval letter confirming the NDA labeling pathway for Pitocin; used only for approved-product and labeling context.
- 3.
PubMed. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis 2018.
doi:10.1002/14651858.CD011689.pub3 PMID:30569545 Accessed 2026-06-09.
Cochrane network meta-analysis source used for obstetric uterotonic evidence context, not for general-use instructions.
- 4.
PubMed. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder 2021.
doi:10.1056/NEJMoa2103583 PMID:34644471 Accessed 2026-06-09.
Large placebo-controlled intranasal oxytocin autism trial used to keep neuro-social claims grounded; it does not show a wellness or social-confidence benefit.
- 5.
FDA oxytocin label. FDA 2022 Oxytocin Injection label.
Approved uses, contraindications, warnings, and labeled obstetric context.
- 6.
FDA Pitocin label. FDA 2014 Pitocin label.
Molecular weight, peptide nature, half-life, and vasopressin-related properties.
- 7.
FDA compounding pages. FDA compounded-drug risk and policy pages.
Compounded drugs are not FDA-approved or pre-reviewed by FDA.
- 8.
FDA nasal-spray CMC guidance. FDA nasal spray chemistry, manufacturing, and controls guidance.
Dose reproducibility, device function, sterility, and formulation expectations.
- 9.
FDA oxytocin nasal 483. FDA Form 483 involving oxytocin nasal spray.
Real-world compounded nasal oxytocin quality failure example.
- 10.
Kosfeld 2005 trust. Kosfeld et al. 2005 trust study.
Early trust narrative.
- 11.
Declerck 2020 replication. Declerck et al. 2020 registered replication.
Replication challenge to the trust narrative.
- 12.
Leppanen 2017 meta-analysis. Leppanen et al. 2017 emotion-recognition meta-analysis.
Acute emotion-recognition signal.
- 13.
Spengler 2017 dose timing. Spengler et al. 2017 dose and timing study plus related neural work.
Mechanism, amygdala, timing, and salience context.
- 14.
Yamasue 2020 ASD RCT. Yamasue et al. 2020 adult autism spectrum disorder randomized trial.
Adult autism trial context.
- 15.
Sikich 2021 ASD trial. Sikich et al. 2021 pediatric autism phase 2 trial.
Large pediatric autism trial context.
- 16.
Guastella 2023 ASD trial. Guastella et al. 2023 young-children autism trial.
Young-child autism trial context.
- 17.
Parker 2017 biomarker. Parker et al. 2017 biomarker-response autism study.
Responder-subgroup hypothesis.
- 18.
Zheng 2019 schizophrenia. Zheng et al. 2019 schizophrenia meta-analysis.
Mixed schizophrenia efficacy signal.
- 19.
Sabe 2021 dose-response. Sabe et al. 2021 dose-response schizophrenia meta-analysis.
Mixed schizophrenia signal.
- 20.
Imamoglu 2024 cognition RCT. Imamoglu et al. 2024 schizophrenia cognition randomized trial.
Cognitive-outcome trial context.
- 21.
Gully 2024 OUD. Gully et al. 2024 opioid-use-disorder cue-reactivity trial.
Substance-use cue-reactivity study context.
- 22.
FOXY 2025 FTD. FOXY 2025 frontotemporal dementia apathy trial.
Frontotemporal-dementia apathy signal.
- 23.
Sexual and couples studies. Sexual-function and couples oxytocin studies.
Small mixed evidence behind libido and intimacy claims.
- 24.
Market and clinic pages. Vendor, clinic, and anecdotal market pages.
Search intent and gray-market narrative only.
- 25.
Veterinary bulk powder. Veterinary non-sterile bulk oxytocin powder label.
Non-human bulk-powder market context.